Mark Jacobson
Directeur des opérations chez AXSOME THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Mark Jacobson
Sociétés | Poste | Début | Fin |
---|---|---|---|
AXSOME THERAPEUTICS, INC. | Directeur des opérations | 01/04/2014 | - |
Investor Relations Contact | 01/04/2014 | - | |
Secrétaire Général | 01/10/2015 | - |
Historique de carrière de Mark Jacobson
Anciens postes connus de Mark Jacobson
Sociétés | Poste | Début | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2009 | 01/03/2014 |
Formation de Mark Jacobson
Iowa State University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AXSOME THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Mark Jacobson
- Expérience